On May 11, 2022, the U.S. Food and Drug Administration (FDA) approved a supplemental application for Opdivo (nivolumab), an immunotherapy developed by Bristol Myers Squibb. This approval specifically pertains to the drug's efficacy, indicating an expansion or modification of its approved uses based on new data.
Background
Nivolumab, marketed as Opdivo, is a well-known immunotherapy agent. This supplemental approval, designated as BLA 125554 S-108, was granted to the sponsor, Bristol Myers Squibb, and is categorized under efficacy. Supplemental applications are typically submitted to the FDA to propose changes to an already approved drug, which can include new indications, new dosing regimens, new patient populations, or updated efficacy data for existing indications. The FDA's review and approval of such applications confirm that the new information supports the drug's effectiveness for the proposed change.
What this means
The FDA's supplemental approval for Opdivo (nivolumab) for efficacy on May 11, 2022, signifies an important update to the drug's prescribing information. While the specific details of the expanded indication or patient population are not provided in the immediate approval notice, this type of approval generally means that new clinical data has demonstrated the drug's effectiveness for an additional use or in a different context than previously approved. This allows clinicians to potentially utilize nivolumab for a broader range of patients or conditions, or with an optimized treatment approach, thereby extending its therapeutic impact. For patients, it could mean access to nivolumab for a previously unapproved condition or as part of an improved treatment strategy.
Source
The information regarding this supplemental FDA approval was obtained from the U.S. Food and Drug Administration (FDA) on May 11, 2022. The approval details for supplemental application BLA 125554 S-108 are publicly accessible on accessdata.fda.gov.